Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $340.00 price target on the stock.
Multiple Sclerosis Drugs Market Outlook 2024-2028, 2033 - A $48 Billion Global Opportunity Dominated by Biogen, Novartis, Roche, Bayer HealthCare, and Pfizer [Yahoo! Finance]
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis [Yahoo! Finance]
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis [Financial Post (Toronto, Ontario, Canada)]
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis